GNPX - Genprex initiates early-stage REQORSA lung cancer study

Genprex (GNPX) announces initiation of the company's phase 1/2 Acclaim-1 clinical trial for REQORSA immunogene therapy in combination with Tagrisso to treat non-small cell lung cancer following U.S. FDA review.The company has engaged its first clinical site for the trial, and Genprex is continuing to work with a number of other important cancer research centers and academic institutions to select optimal study sites.Genprex expects the Phase 1 portion of the study to enroll up to 18 patients at three clinical sites and for the Phase 2 portion to enroll ~74 patients at up to 15 clinical sites.The first part of the Phase 1/2 clinical trial will be a dose escalation study.The primary endpoint of the Phase 2 portion of the trial is progression-free survival, which is defined as time from randomization after first progression on Tagrisso, to first event (second progression) or death.Shares up more than 2% premarket.Genprex had in-licensed additional gene therapy technologies

For further details see:

Genprex initiates early-stage REQORSA lung cancer study